Motor vehicle accidents: How should cirrhotic patients be managed?

Takumi Kawaguchi, Eitaro Taniguchi, Michio Sata

Takumi Kawaguchi, Eitaro Taniguchi, Michio Sata, Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan

Abstract

Motor vehicle accidents (MVAs) are serious social issues worldwide and driver illness is an important cause of MVAs. Minimal hepatic encephalopathy (MHE) is a complex cognitive dysfunction with attention deficit, which frequently occurs in cirrhotic patients independent of severity of liver disease. Although MHE is known as a risk factor for MVAs, the impact of diagnosis and treatment of MHE on MVA-related societal costs is largely unknown. Recently, Bajaj et al. demonstrated valuable findings that the diagnosis of MHE by rapid screening using the inhibitory control test (ICT), and subsequent treatment with lactulose could substantially reduce the societal costs by preventing MVAs. Besides the ICT and lactulose, there are various diagnostic tools and therapeutic strategies for MHE. In this commentary, we discussed a current issue of diagnostic tools for MHE, including neuropsychological tests. We also discussed the advantages of the other therapeutic strategies for MHE, such as intake of a regular breakfast and coffee, and supplementation with zinc and branched chain amino acids, on the MVA-related societal costs.

INVITED COMMENTARY ON HOT ARTICLES

We have read with great interest the recent article by Bajaj et al. describing the diagnosis and treatment of minimal hepatic encephalopathy (MHE) to prevent motor vehicle accidents (MVAs), and would strongly recommend it to the readers.

MVAs are serious social issues worldwide. Various factors are intricately involved in the occurrence of MVAs, and driver illness is an important cause. Besides acute myocardial infarction, epileptic seizure, and hypoglycemia related to the use of anti-diabetic agents, liver cirrhosis with MHE has been reported to increase the risk of MVAs. Although MHE occurs in up to 80% of patients with chronic liver disease and diagnostic tools and therapeutic strategies for MHE exist, little information is available about the management of patients with liver cirrhosis with regard to preventing MVAs and subsequently reducing the associated societal costs.
In their study, Bajaj et al\(^1\) performed a cost-effectiveness analysis to identify management strategies for the diagnosis and treatment of MHE in patients with liver cirrhosis to reduce MVA-related societal costs. They found that the diagnosis of MHE by rapid screening using the inhibitory control test (ICT), and subsequent treatment with lactulose could substantially reduce societal costs. This is a significant study, and we agree with the authors about the benefits of the use of the diagnostic test and therapeutic management. However, we suggest that the management strategy should be modified to some extent for use in general medical institutions to prevent MVAs on a larger scale.

The ICT is a computerized test of attention and response inhibition that has been used to characterize attention deficit disorders\(^2,3\). The ICT consists of the presentation of several letters at 0.5 s intervals, while the subject is instructed to respond or inhibit their response to the specific letter\(^2,3\). The ICT is considered reliable and sensitive for the diagnosis of MHE\(^2,3,13\). In addition, unlike standard neuropsychological tests, ICT results are significantly associated with the future occurrence of MVAs\(^4\). However, the test takes approximately 30 min to complete and patients need to be familiar with computer operation. Furthermore, validation and standardization are required for each population, and therefore, so far, the ICT is not universally accessible. Similarly, other diagnostic tools for MHE also require trained personnel and specialized equipment\(^5\). In fact, an American Association for the Study of Liver Disease (AASLD) survey showed that the majority of AASLD members are not able to test for MHE because of a lack of time, resources, and suitable personnel\(^1,4\). Along with Bajaj et al\(^1,4\), we propose that rapid and simple tools for the diagnosis MHE should be developed urgently, such as biochemical tests or virtual reality driving simulations.

Lactulose has been used to treat hepatic encephalopathy since 1966\(^6,7\). Lactulose reduces blood ammonia levels and improves overt hepatic encephalopathy as well as MHE\(^7\). In their study, Bajaj et al\(^1\) have demonstrated the benefits of lactulose therapy on the occurrence of MVAs and MVA-related societal costs. However, compliance with lactulose treatment is generally poor, primarily because of its side-effects such as abdominal discomfort\(^1,6,7\). Recently, other therapeutic strategies for MHE have been reported. First, as prolonged periods of fasting are linked to the development of MHE, having a regular breakfast improves the attention and executive functions of cirrhotic patients with MHE\(^8\). Second, coffee intake improves cognitive function in elderly people as well as in patients with type 2 diabetes mellitus\(^9,10\). Although the beneficial effects of coffee on cognitive function have never been investigated in cirrhotic patients, insulin resistance is frequently seen in patients with chronic liver disease\(^11,12\). In addition, coffee consumption is known to improve hepatic inflammation and fibrosis in patients with chronic liver disease\(^13\). Third, the blood ammonia level is regulated by the activity of ornithine transcarbamoylase and zinc is a coenzyme required for its up-regulation\(^14\).

Oral zinc supplementation improves hyperammonemia as well as hepatic encephalopathy, as seen in a double-blind randomized controlled trial\(^15\). Finally, a decrease in serum branched chain amino acids (BCAA) levels is a feature of chronic liver disease\(^16\). BCAA is a source of glutamate, which detoxifies ammonia by glutamine synthesis in the skeletal muscle and brain\(^17,18\). Therefore, BCAA enhances the detoxification of blood ammonia by incorporating ammonia in the process of glutamine production and is currently used for treating patients with hepatic encephalopathy\(^19\). Thus, a therapeutic approach comprising the intake of a regular breakfast and coffee, and supplementation with zinc and BCAA may improve the cost-effectiveness of MVA-related events in cirrhotic patients with MHE (Figure 1).

Prevention of MVA by the diagnosis and treatment of MHE is an important component in the management of patients with liver cirrhosis. Collaborative researches among medical institutions, automobile companies, and governmental sectors may help further prevent MVAs and subsequently reduce MVA-related societal costs.

![Figure 1 A proposed flow chart of drive permission for patients with chronic liver disease, MHE: Minimal hepatic encephalopathy, BCAA: Branched chain amino acids.](image_url)

### REFERENCES

1. Bajaj JS, Pinkerton SD, Sanval AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. *Hepatology* 2012; 55: 1164-1171

2. Huchner WW, Wojcik NC, Jorgensen G, Marcolla SP, Nicolich MJ. Mortality patterns and trends among 49,705 U.S.-based women in a petroleum company: update 1979-2000. *J Occup Environ Med* 2010; 52: 99-108

3. Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, Gibson DP, Hoffmann RG, Stravitz RT, Heuman
DM, Sterling RK, Shiffman M, Topaz A, Boyett S, Bell D, Sanyal AJ. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175-1183

4 Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14: 3690-3695

5 Bajaj JS, Hafeezullah M, Hoffmann RG, Saewan K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 1903-1909

6 Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739-745

7 Watanabe A, Sakai T, Sato S, Imai F, Ohoto M, Arakawa Y, Toda G, Kobayashi K, Muto Y, Tsujii T, Kawasaki H, Okita K, Tanakatatsu K, Fujinuma S, Shimada S. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410-1414

8 Kato A, Suzuki K, Kaneta H, Obara H, Fujishima Y, Satoh S. Regional differences in cerebral glucose metabolism in cirrhotic patients with subclinical hepatic encephalopathy using positron emission tomography. Hepatol Res 2000; 17: 227-245

9 Kato A, Kato M, Ishii H, Ichimiya Y, Suzuki K, Kawasaki H, Yamamoto SI, Kumashiro R, Yamamoto K, Kawamura N, Hayashi N, Matsuzaki S, Terano A, Okita K, Watanabe A. Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteria: multicenter collaborative study in Japanese. Hepatol Res 2004; 30: 71-78

10 Sugimoto R, Iwasa M, Maeda M, Urawa N, Tanaka H, Fujita N, Kobayashi Y, Takeda K, Kaito M, Takei Y. Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1413-1420

11 Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Buttersworth R, Duseja A, Aggarwal R, Amaraparakar D, Sharma P, Madan K, Shah S, Seth AK, Gupta RK, Koshy A, Rai RR, Dilawari JB, Mishra SP, Acharya SK. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol 2010; 25: 1029-1041

12 Crosbie J, Pérusse D, Barr CL, Schachar RJ. Validating psychiatric endophenotypes: inhibitory control and attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2008; 32: 40-55

13 Bajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, Hirschke D, Hammke TA, Pinkerton SD, Saewan K. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008; 135: 1591-1600

14 Bajaj JS, Etendenian A, Hafeezullah M, Saewan K. Testing for minimal hepatic encephalopathy in the United States: An AASLD survey. Hepatology 2007; 45: 833-834

15 Bircher J, Müller J, Guggenheim P, Haemmerli UP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1966; 1: 890-892

16 Kalaitzakis E, Björnsson E. Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health-related quality of life. Hepatology 2007; 46: 949-50; author reply 951

17 Horomans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997; 11: 165-170

18 Vaisman N, Katzman H, Carmiel-Haggiag M, Lusthaus M, Niv E. Breakfast improves cognitive function in cirrhotic patients with cognitive impairment. Am J Clin Nutr 2010; 92: 137-140

19 Croytey V, Crof T, Silber B, Neale C, Schloery A, Stough C, Schmitt J. Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study. Psychopharmacology (Berlin) 2012; 219: 737-749

20 Biessels GJ. Caffeine, diabetes, cognition, and dementia. J Alzheimers Dis 2010; 20 Suppl 1: S143-S150

21 Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508

22 Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, 2007; 237-245

23 Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34: 297-305

24 Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol 2010; 16: 1943-1952

25 Reding P, Duchateau J, Bailleul C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984; 2: 493-495

26 Katayama K. Ammonia metabolism in hepatic encephalopathy. Hepatol Res 2004; 305: 73-80

27 Reding P, Duchateau J, Bailleul C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984; 2: 493-495

28 Platell C, Kong SE, McCauley R, HallJC. Branched-chain amino acids. J Gastroenterol Hepatol 2000; 15: 706-717

29 Moriwaki H, Shiraki M, Fukushima H, Shimizu M, Iwasa J, Naiki T, Nagaki M. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res 2008; 38: S102-S106